Cure8 news brief
New Phase 3 AFFIRM data for subcutaneous Skyrizi (risankizumab) in Crohn’s disease was released and coincided with a notable AbbVie stock drop, suggesting investor concern about the results.
People with IBD may want to watch for full clinical reports and regulatory or expert commentary to understand what the data mean for treatment.
Patients with Crohn’s disease (particularly those on biologics), clinicians treating IBD, researchers tracking IL-23 inhibitors, and investors following AbbVie.
The article is a market/finance brief noting timing: the AFFIRM Phase 3 readout for subcutaneous Skyrizi in Crohn’s disease hit the wire and AbbVie shares slid about 3.1% afterward.
The story focuses on investor interpretation of the data rather than clinical details; the piece does not provide efficacy or safety results, trial numbers, or regulatory conclusions. If you want clinical takeaways, look for the full AFFIRM study report, AbbVie’s press release, and analysis from clinical journals or gastroenterology societies.
Those sources are needed to understand actual efficacy, safety, and implications for treatment.
This article is a finance/market brief emphasizing the timing of a stock move around the AFFIRM Phase 3 readout; it does not include trial results, safety information, or regulatory actions. Look for AbbVie’s official release and peer-reviewed or conference reports for clinical details.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A subcutaneous induction option could make starting risankizumab easier and less burdensome than IV infusions for many people with Crohn's disease, potentially expanding access and convenience.
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
A new subcutaneous option for risankizumab (SKYRIZI) showed higher rates of endoscopic remission and ulcer-free endoscopy versus placebo in a Phase 3 Crohn's disease trial, which could expand at-home biologic options if...
